Table 1.
Baseline characteristics of the study participants.
| Variables | RA Patients (N = 479) |
|---|---|
| Age (year) | 61.8 ± 11.5 |
| Sex (female) | 426 (88.9%) |
| Menopause | 353 (82.9%) |
| Weight (kg) | 55.4 (49.2–62.8) |
| Height (cm) | 155.3 (150.1–160) |
| BMI (kg/m2) | 23.1 (20.9–25) |
| Smoking | 33 (6.9%) |
| Alcohol | 41 (8.6%) |
| Disease duration (month) | 53 (33–72) |
| 1987 ACR criteria | 377 (78.7%) |
| 2010 ACR/EULAR criteria | 418 (87.2%) |
| RF titer (IU/mL) | 67.2 (24–165.2) |
| ACPA titer (U/mL) | 78 (0.4–179.1) |
| RF positive | 380 (79.3%) |
| ACPA positive | 295 (61.6%) |
| ESR (mm/h) | 15 (7–29) |
| CRP (mg/L) | 0.18 (0.05–0.79) |
| Medications | |
| Glucocorticoid | 442 (92.3%) |
| Prednisolone-equivalent dose (mg/day) | 2.5 (1.25–5) |
| NSAID | 341 (71.2%) |
| Biologics | 56 (11.7%) |
| Vitamin D | 228 (47.6%) |
| Calcium | 195 (40.7%) |
| Proton pump inhibitor | 123 (25.7%) |
| Treatment for osteoporosis | 262 (54.7%) |
| Bisphosphonate | 189 (39.5%) |
| SERM | 98 (20.5%) |
| Vertebral fracture | 81 (16.9%) |
| Age (year) | 69.5 ± 9.3 |
| Male | 7 (8.6%) |
| Postmenopausal woman | 74 (91.4%) |
BMI, body mass index; ACR, American college of rheumatology; EULAR, European League Against Rheumatism; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibody; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NSAID, non-steroidal anti-inflammatory drug; SERM, selective estrogen receptor modulator. Values were represented as mean ± standard deviation. Values that were not normally distributed are represented as medians (IQR).